therapeutic ratio (benefit to risk) for inhaled ponent of overall systemic absorption and will determine the systemic bioactivity profile. It is therefore conceivable that patients with more severe asthma may be protected from systemic effects as a consequence of reduced lung bioavailability of the inhaled fraction. For the intranasal route there is also no first pass effect so absorption of unchanged drug will occur directly into the systemic circulation as with the lung. Whilst there is a high degree of intranasal deposition, it is also important to consider rapid nasociliary clearance into the throat as well as the relative mucosal surface area for absorption ( fig 2) . The situation for beclomethasone dipropionate is somewhat different in that there is a degree of first pass activation and inactivation for this compound in the lung and nose as well as in the liver. Pharmacological properties such as glucocorticoid receptor potency, affinity, and residency time will in part determine the systemic pharmacodynamic response. In addition, pharmacokinetic factors including plasma elimination half life and volume of distribution (due to lipophilicity) will contribute to effects at steady state in terms of drug accumulation in the blood and retention in systemic tissue. The main focus of this review is to evaluate the different measures of systemic bioactivity scope of this review article. The pharmaco-
Intracellular action requires both cytoplasmic glucocorticoid receptors (GR), which are genetically polymorphic and thus vary in their affinity for steroids, and accessory "heat
kinetics and dose response relationships for shock proteins" (HSPs) . GR in plasma cortisol levels with peak levels usually occurring no later than 08.00 hours and up to a threefold difference in levels between 08.00 and 10.00 hours. 8 9 Even with strict standardisation of the collection time at 08.00 hours there remains a considerable degree of intraindividual and inter-individual variability which makes a single morning plasma cortisol estimate a relatively insensitive end point for detecting suppression of HPA axis activity. The measurement of a single plasma level of ACTH at 08.00 hours is more variable and of even less value than a single measurement of plasma cortisol at 08.00 hours because of the pulsatile nature of the ACTH release throughout the ment of a 24 hour plasma cortisol profile is impractical as this requires frequent venous sampling, whilst the compliance with a 24 hour urine collection is often poor unless the subject Hypothalamic-pituitary-adrenal (HPA)
is closely supervised during a period of conaxis activity finement. Neither of these tests is therefore It is well recognised that measures of HPA axis ideal for screening HPA axis activity either activity can be used to demonstrate the dose for outpatient studies or for everyday clinical response effects of inhaled corticosteroids in practice. terms of their systemic bioactivity. These effects
The 24 hour urinary free cortisol excretion of exogenous corticosteroids occur as a conhas been shown to be more sensitive at desequence of their negative feedback on the HPA tecting adrenal suppression than a single plasma cortisol sample at 09.00 hours and has comparable sensitivity to a 250 g bolus dose of ACTH stimulation or an insulin stress test.
10
The use of timed fractionated collections to measure urinary free cortisol excretion has been investigated in order to obviate the compliance and variability problems associated with a 24 24 hour collection, particularly when corrected peatedly exposed to tetracosactrin, physicians need to be aware of this limitation and have for creatinine excretion.
11 In a recent short term, steady state, dose ranging evaluation of immediate access to resuscitation equipment.
It has been shown that the use of much lower inhaled fluticasone propionate and budesonide in adult asthmatic subjects at a dose of 250 g doses of tetracosactrin (0.5-1 g) is as effective in producing a cortisol response, correlating twice daily there was a mean treatment difference of 50% for suppression of the overnight well with an insulin stress test, and it may be superior to the higher dose 250 g ACTH test urinary cortisol/creatinine ratio compared with a 23% difference for suppression of 08.00 hours in detecting subtle defects of adrenal reserve. [16] [17] [18] Indeed, in a study of asthmatic chilplasma cortisol level, suggesting that the urinary ratio may be a more sensitive measure. 12 dren and adults receiving long term inhaled beclomethasone dipropionate (median daily However, the clinical relevance of such differences would require a dynamic test of adrenal dose 482 g/m 2 ) and budesonide (median daily dose 507 g/m 2 ) it was found that 24% of reserve during longer term therapy.
In everyday clinical practice the doctor is cases had an insufficient response to 0.5 g of tetracosactrin but exhibited a normal response dealing with an individual rather than an average patient, and it is therefore more relevant with 250 g of tetracosactrin.
19 This in turn suggests that, in patients receiving inhaled to look at individual responses. Thus, in the study by Clark et al 12 the number of low over-corticosteroids, the high dose tetracosactrin test may be associated with a substantial rate of false night urinary cortisol values was 21 out of 36 for fluticasone propionate compared with three negative results and may be a poor predictor of clinically relevant impaired adrenal reserve. out of 36 for budesonide over a dose range of 250 g, 500 g, and 1000 g twice daily. Interestingly, measurements of 24 hour urinary cortisol in the same study 19 also distinguished However, it is evident on inspecting these data that there is considerable inter-individual vari-between responders and non-responders to low dose tetracosactrin stimulation. Although the ability in urinary cortisol suppression for a given dose of inhaled corticosteroid. This is insulin stress test assesses the integrity of the whole HPA axis, it is rarely used because it particularly the case at lower doses of inhaled corticosteroid, making it very difficult for the is potentially hazardous and unpleasant for patients. clinician to predict whether a given patient will have an abnormal response. Interestingly, It would therefore appear that the low dose tetracosactrin stimulation test may be a better studies with inhaled budesonide in children have shown remarkably little evidence of basal mimic of a physiological stress response than the high dose test, the latter being more recortisol suppression as assessed by overnight urinary cortisol/creatinine excretion. 13 This flective of a pharmacological response. Another way of measuring adrenal reserve is to use CRH probably reflects the shorter half life of budesonide (1.5 hours) and a greater degree which has the advantage of evaluating the status of the anterior pituitary gland as well as the of systemic clearance in children.
14 A 24 hour collection for urinary cortisol metabolites may adrenal cortex, whereas tetracosactrin only stimulates the cortex. Synthetic human CRH also be used to assess adrenocortical excretion rates, 15 although this test is more difficult and in a bolus dose of 100 g has been shown to correlate well with an insulin stress test in expensive than measurement of urinary free cortisol. Since it is not available in most service discriminating impaired adrenal reserve in patients receiving oral prednisolone. 20 In a laboratories in the United Kingdom, it has therefore not gained widespread acceptance. study of asthmatic patients in which placebo was compared with 1000 g inhaled budesonThe above screening tests may be used to detect endogenous adrenocortical activity and ide twice daily it was shown that depression of basal 08.00 hours cortisol and ACTH was should be used merely as a marker of potential for systemic activity by a given dose of inhaled associated with a comparable degree of blunting of the peak cortisol and ACTH response corticosteroid. Prolonged exposure to exogenous systemic corticosteroid results in sup-to stimulation with a 100 g bolus of human CRH. 21 The disadvantage of the CRH stimupressed ACTH levels and adrenocortical atrophy. In order to ascertain the clinical rel-lation test is that it requires more frequent blood sampling over a 120 minute period for evance of long term adrenal suppression it is necessary to perform a dynamic stimulation test both cortisol and ACTH compared with a single 30 minute cortisol sample after stimuto evaluate adrenal reserve, as this is thought to mimic the physiological response to stress. lation with the short tetracosactrin test. More information is required on the relative sensiConventionally, most clinicians have used the ACTH stimulation test, measuring the cortisol tivity and reproducibility of the CRH test compared with the low dose tetracosactrin test and response to a high supraphysiological intravenous dose (250 g) of synthetic ACTH ana-the insulin stress test in patients receiving long term inhaled corticosteroids, before its use can logue (tetracosactrin) given as a bolus or a six hour infusion. Unfortunately, at least in the be advocated for routine clinical practice.
Another relevant question is whether the UK, the routine use of this test is questionable as the use of Synacthen (Ciba Pharmaceuticals) degree of HPA axis suppression wanes with time during repeated exposure to inhaled is contraindicated on the data sheet for allergic or asthmatic subjects because of occasional case corticosteroid as a result of receptor downregulation at the level of the hypothalamus reports of hypersensitivity reactions, including anaphylactic shock. Whilst this is most prob-or pituitary. In the short term, exposure to intranasal fluticasone (200 g/day) or budesonably due to sensitisation in individuals regroup.bmj.com on April 13, 2017 -Published by http://thorax.bmj.com/ Downloaded from ide (400 g/day) for one week resulted in a for one month followed by 400 g/m 2 for four months revealed a 28% fall in PICP and a 6% significant reduction in serum cortisol and osteocalcin levels at 08.00 hours with little or fall in osteocalcin. 26 In asthmatic adults treated for six weeks no further change after a second week at double the dose. 22 This may indicate the occurrence with beclomethasone dipropionate 1500 g/ day there was a small but significant decrease of desensitisation or a "floor effect" in response. Measurement of lymphocyte glucocorticoid re-in osteocalcin (18%) and PICP (22%), whereas half the dose of fluticasone had no significant ceptor mRNA expression also showed attenuation with both drugs which essentially effect. 27 In contrast, in a two week crossover study with healthy volunteers given either reached a plateau level after the first week. After a third week of washout, glucocorticoid budesonide 1600 g/day or fluticasone 1500 g/day there was a paradoxical decrease receptor mRNA remained significantly blunted in the group receiving fluticasone but not in bone resorption in terms of a reduction in carboxyterminal telopeptide of type I probudesonide (36% fall versus 7% fall), in keeping with more prolonged retention of flu-collagen (ICTP) and a fall in 24 hour urinary calcium. 28 A similar paradoxical short term rise ticasone in the systemic compartment. In the same subjects, topical effects assessed on nasal in PICP has been observed after treatment for four weeks with 800 g/day budesonide almucosal biopsy samples showed a similar pattern in terms of reduced expression of glu-though this was no longer evident after 2.5 years. 29 cocorticoid mRNA during treatment, although levels remained suppressed after washout with Hanania et al showed that a dose response effect on bone mineral density was seen in both drugs for up to six weeks. 23 These data also showed inter-individual and tissue specific patients receiving inhaled budesonide and beclomethasone dipropionate in doses above variation in glucocorticoid receptor regulation.
Similar studies with these molecular probes 800 g/day for a median duration of two years.
30
Toogood et al 31 also demonstrated a dose reare required in asthmatic subjects to look at the effects of inhaled corticosteroids. Whether sponse effect of inhaled beclomethasone and budesonide taken over 10 years, with a 2 mg the mRNA changes are faithfully translated into altered receptor density is also unclear in daily dose resulting in a reduction in bone density of one standard deviation which implies the crucial regions of the HPA axis responsible for feedback and other regions of potential a 1.5-3-fold increased life time risk of fracture resulting from osteoporosis. Their data also glucocorticoid toxicity. In a longer term study inhaled fluticasone propionate 2 mg/day and suggested that, in patients who were previously dependent on prednisone, the subsequent use beclomethasone dipropionate 1.6 mg/day were administered for 12 weeks to patients with of long term inhaled corticosteroids may result in a reduced risk of vertebral fracture in keeping moderate to severe asthma. 24 The degree of suppression of morning serum cortisol with an improved benefit to risk ratio for inhaled versus oral corticosteroid therapy. (08.00-10.00 hours) was found to be 132 nmol/l from baseline after four weeks on Furthermore, bone density was increased in association with supplemental oestrogen thertreatment and was unchanged at 12 weeks (133 nmol/l). Unfortunately, measurements apy in postmenopausal women, suggesting a protective effect of hormone replacement therwere not made prior to four weeks and so it is unclear whether subsensitivity may have oc-apy in this group of patients. In two separate studies of asthmatic children receiving up to curred in the initial phase of treatment. Additional complexities which may underpin 400 g/day of beclomethasone dipropionate for six months there has been no detectable adverse inter-individual variation in the glucocorticoid response include known receptor poly-effect on vertebral bone mineral density. 32 33 Comparison with measures of HPA axis acmorphisms, prereceptor metabolism, and interactions at the level of control of transcription of tivity suggests that bone markers are in general less sensitive at picking up systemic effects of the target gene, all of which show documented variation (fig 1) . inhaled corticosteroids. In a study with 1000 g twice daily fluticasone propionate and budesonide in adult asthmatics there was a 45% and 17% fall, respectively, in 08.00 hours Bone metabolism Biochemical markers of bone formation (osteo-serum cortisol levels compared with a 28% and 7% fall in osteocalcin and a 9% and 3% fall blast activity) and bone resorption (osteoclast activity) have been employed to evaluate in PICP. 34 However, in a study reported by Knuttson et al treatment for one week with systemic bioactivity, although markers of bone resorption tend to be less sensitive. In a study intranasal fluticasone propionate 200 g/day produced a 37% fall in serum cortisol levels at comparing various markers of bone metabolism in asthmatic children receiving 800 g/day 08.00 hours and a 43% fall in serum osteocalcin levels at 08.00 hours, with corresponding figbeclomethasone dipropionate or budesonide for two weeks it was shown that markers of ures for 400 g/day aqueous budesonide of 26% and 53%. 22 At first glance the latter results collagen formation -namely, aminoterminal propeptide of type III procollagen (PIIINP) might be surprising, given the relatively small mucosal surface area for intranasal absorption, and carboxyterminal propeptide of type I procollagen (PICP) -were the most sensitive in-although this may be offset by a larger proportion of the nominal dose being deposited in dices showing a 36% and 20% fall, respectively. 25 Similar data in asthmatic chil-the nose than in the lung (fig 2) . Pharmacokinetic studies with direct instillation of dren receiving budesonide 800 g/m 2 per day group.bmj.com on April 13, 2017 -Published by http://thorax.bmj.com/ Downloaded from radiolabelled intranasal budesonide have density and, in particular, studies are needed to assess what happens to these children once shown that it exhibits approximately 100% systemic bioavailability. 35 However, in real life they enter adulthood. However, it should be emphasised that, for most children with the total systemic bioavailability of the nominal dose is more likely to be 30-40% because of asthma, the use of conventional doses of inhaled corticosteroid (400 g/day or less) is an rapid nasociliary clearance into the throat. The data of Knutsson et al 22 show that systemic effective and safe treatment option which is very unlikely to have adverse effects on bone absorption must have occurred directly from the nose where there is no first pass metabolism metabolism or growth in the long term. Even at high doses of inhaled corticosteroids the for either budesonide or fluticasone. This is supported by another study in patients with benefit to risk ratio is much better than that of oral prednisolone in doses required to achieve rhinitis where 200 g/day of intranasal aqueous fluticasone produced a 13% fall in urinary 24 comparable anti-asthmatic control. High dose inhaled corticosteroids therefore remain the hour free cortisol and a 37% fall in the blood eosinophil count. 36 current preferred treatment option for the small proportion of severe cases who require them.
Growth in children The systemic effects of inhaled corticosteroid Conclusions
The dose related systemic adverse effects of on short term growth velocity can be assessed accurately and reproducibly using the tech-inhaled corticosteroids can be reproducibly evaluated using measures of HPA axis activity. nique of knemometry which electronically measures lower leg growth to within 0.2 mm. Although there is considerable inter-individual variability in adrenal suppression at a given It is possible to show a dose response effect with inhaled budesonide (200-800 g) on kne-dose of inhaled corticosteroid, in general the dose response curve is relatively flat below mometry at doses which have no detectable suppression of 24 hour urinary cortisol. 37 In 800 g/day in adults and 400 g/day in children. Measurements of HPA axis activity are another study greater effects on knemometry were found with beclomethasone 400 g/day more sensitive than biochemical indices of bone metabolism for detecting systemic bioactivity and 800 g/day than with fluticasone 200 g/ day. 38 These findings suggest that knemometry of inhaled corticosteroids. Further work is required to evaluate whether polymorphism of is a particularly sensitive marker of systemic bioactivity in children receiving inhaled cortico-the glucocorticoid receptor is responsible for the variation in response, as this may enable steroid therapy even at conventional dosage. However, it would appear that short term us to identify at risk individuals with a greater propensity for long term systemic effects. Howeffects on knemometry do not predict effects on long term statural height as measured with ever, it should be appreciated that the measurement of adrenocortical activity represents a a stadiometer. 39 Indeed, in a prospective 3-5 year cohort follow up of asthmatic children no marker for evaluating potential systemic toxicity rather than being indicative of clinically evidence of growth suppression was found with inhaled budesonide at doses of 400 g/day. 40 relevant impaired adrenal function.
In everyday clinical practice there is good Doses of inhaled fluticasone and budesonide (200-400 g/day) in children are not associated rationale for measuring systemic activity in patients who require maintenance therapy with with any alteration in biochemical bone markers, suggesting that these may also be higher doses of inhaled corticosteroid such as >400 g/day in children and >800 g/day in relatively insensitive measures of systemic bioactivity in children as well as adults. 41 Recent adults. One of the more reproducible and practical screening measurements of HPA axis accase reports in children 42 of adrenal and growth suppression in association with high doses of tivity for use in clinical practice is the overnight urinary-free cortisol collection which may be fluticasone propionate (>1000 g/day) should be interpreted with caution until results of further refined by correcting for creatinine and can be used in both adults and children. Norproperly controlled long term studies with more conventional doses are available.
mal reference ranges should be set up for an individual laboratory for a given type of assay. There is now increasing evidence to suggest that suppressing asthmatic disease activity in Patients with an abnormally low urinary cortisol value should have this repeated on a second children will usually outweigh any potential systemic adverse effects of inhaled cortico-occasion and, if it remains lower than the normal reference range, it should be followed by steroid in terms of determining long term growth. 43 44 It is likely that with high doses of some form of stimulation test to evaluate the degree of adrenocortical reserve. The use of inhaled corticosteroid in children that there may be a delay in the pubertal growth spurt, the low dose (0.5 g) tetracosactrin test is likely to be a more appropriate physiological stimulus but after a subsequent "catch-up" phase in growth velocity there will be little difference in and is more sensitive than the higher 250 g dose. The CRH stimulation test is a possible the final height. 45 46 Furthermore, in asthmatic children with stunted growth there appears to alternative, but more data are required for its evaluation as a measure of impaired reserve in be no evidence of any effect of disease or treatment on the growth hormone axis. 47 It is patients receiving long term inhaled corticosteroids. not clear, however, whether long term effects of high doses of inhaled corticosteroids in children
In clinical practice a single measurement of bone density may be of value in at risk patients will adversely affect bone mineralisation and of bioavailability from the lung and the nose 27 Bootsma GP, Dekhuijzen R, Festen J, Mulder PGH, Swinkels LMJW, van Herwaarden CLA. Fluticasone prowill contribute in an additive fashion to the pionate does not influence bone metabolism in contrast long term overall systemic burden.
